We’re at the height of the Streaming Wars, and deciding for which platform you’re willing to pay a premium can be as challenging as figuring out your favorite ice cream on a hot summer’s day.

The relief package contains a homestead exemption — championed by Republican Gov. Greg Gianforte, that taxes second homes at a higher rate than owner-occupied homes. To prioritize residential ...

Lead drug Eylea had global sales of just under $10 billion in 2024 and is approved for wet age-related macular degeneration and other eye-related indications. The majority of sales are for ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Eylea sales fell 26% to $1.04 billion amid pricing pressure and market share loss; Eylea HD saw increased volume. Don’t miss this list of 10 overlooked stocks—including one paying a 9% ...

Total revenues decreased 4% year over year to $3 billion due to lower sales of lead drug Eylea. Revenues also missed the Zacks Consensus Estimate of $3.27 billion. Sales of oncology drug ...

The Legislative Service Commission wrote in an analysis that the team’s revenue estimates were “overly optimistic,” and Office of Budget and Management Director Kim Murnieks wrote that the bond ...

U.S. sales of Eylea, jointly developed with Bayer, fell 26% in the first quarter to $1.04 billion. First-quarter revenue was $3.03 billion, below expectations of $3.27 billion.

Accused of “warming the market” for a new Eylea indication, the German drugmaker successfully argued on appeal that an advisory board was in fact legitimate. An anonymous complainant sparked ...

Meanwhile, its high-dose version, known as Eylea HD, brought in $453M, with over a twofold rise from the prior year period. Meanwhile, REGN’s asthma drug Dupixent, marketed with Sanofi (SNY ...

(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied ...